Approval of the 2022 Annual Report and 2022 Management Report, results appropriation, and discharge
The shareholders endorsed the Annual Report, the consolidated financial statements and the statutory financial statements for 2022, the Management Report and the appropriation of the net loss. Furthermore, the shareholders granted discharge to the members of the Board of Directors and Executive Management for the financial year 2022.
Members of the Board of Directors and the Compensation Committee re-elected
Shareholders re-elected
Statutory Auditors and Independent Proxy re-elected
Shareholders re-elected
Compensation Report and remuneration for Board and Executive Management approved
In a consultative vote, the shareholders endorsed the Compensation Report 2022. In separate binding votes, the shareholders agreed to the compensation for members of the Board of Directors (maximum total amount of compensation covering the period from the 2023 AGM to the 2024 AGM) and for the members of the Executive Management (maximum total amount of fixed compensation for 2023).
Consent to conditional capital increase
The shareholders approved a conditional capital increase by
AGM documents
The “Invitation to the 2023 Annual General Meeting” with full proposals and explanations on the agenda items are available on Kinarus’ website at https://ir.kinarus.com/2023-agm/. From the end of next week, the minutes of the 2023 AGM will also be available.
Kinarus
Contacts
Hochbergerstrasse 60C 4057 +41 61 633 29 71 info@kinarus.com | Investors & Media +41 79 367 6254 chris.maggos@cohesionbureau.com |
Legal disclaimer
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL NOR AN INTIMATION TO SUBMIT A PROPOSAL FOR THE ACQUISITION OF SECURITIES OF KINARUS THERAPEUTICS HOLDING AG. THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN ANY JURISDICTION WHERE IT IS UNLAWFUL TO BE DISTRIBUTED.
Attachment
- PDF Version
© OMX, source